នាយកប្រតិបត្តិ Biogen លាឈប់ពីតំណែង បន្ទាប់ពីតស៊ូជាមួយថ្នាំ Alzheimer's Aduhelm

Topline

Biogen CEO Michel Vounatsos will step down as the company continues to cut about $1 billion in costs annually, Biogen said Tuesday, after Medicare limited coverage for its Alzheimer’s drug, Aduhelm, to patients in clinical trials last month.

ការពិតសំខាន់

Biogen said in a សេចក្តី​ប្រកាស​ព័ត៌មាន Vounatsos will continue to serve as CEO and remain on the company’s board until a new successor is chosen.

Vounatsos said in a statement he is proud of Biogen’s “unparalleled capabilities” in neuroscience, and that he is leaving in a “time of promise” for the company.

The company also said it will substantially eliminate the sales infrastructure related to Aduhelm, along with other cost reductions, which are intended to provide annual savings of $500 million.

This is in addition to the $500 million cost-cutting initiatives Biogen បានប្រកាស in December, according to the company, bringing the annual cost-saving goal to $1 billion.

Biogen shares rose 3% Tuesday morning following the announcement.

សាវតាសំខាន់

រដ្ឋបាលអាហារនិងឱសថ បានអនុម័ត Aduhelm for use in patients with mild cognitive impairment due to Alzheimer’s disease in June, but weeks later two congressional committees opened investigations into the FDA’s approval process for the drug. Lawmakers បានអះអាង the FDA ignored concerns from experts regarding the clinical benefits of the drug, and raised concerns of their own over the drug’s then-$56,000 annual price tag. Three members of the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee លាលែងពីតំណែង following the approval of Aduhelm, and 18 dementia researchers wrote in a សេចក្តីថ្លែងការណ៍ last year they did not think the drug had any meaningful benefits. The FDA has launched an ការពិនិត្យផ្ទៃក្នុង of its approval process for Aduhelm, and the Centers for Medicare and Medicaid Services restricted coverage of the drug last month to patients participating in clinical trials—greatly reducing the number of patients who might otherwise take it.

លេខធំ

$28,200. That’s how much Biogen now ការចោទប្រកាន់ for one year of Aduhelm, after an initial ស្លាក​តម្លៃ នៃ $ 56,000 ។

តង់ហ្សង់។

Stat reports at least 15 hospitals, including Cleveland Clinic, Johns Hopkins, the University of California Los Angeles and the University of Michigan, have decided not to offer Aduhelm to patients, citing a lack of evidence of the drug’s effectiveness.

អានបន្ថែម

Medicare ស្វែងរកការកំណត់ការរ៉ាប់រងសម្រាប់ថ្នាំ Alzheimer's ចម្រូងចម្រាស Aduhelm (ទស្សនាវដ្តី Forbes)

House committees step up investigation into FDA approval of controversial Alzheimer’s drug (ក ស៊ីនតោនប៉ុស្តិ៍)